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Abstract
Objective—We sought to develop a murine model to examine the antithrombotic and
antiinflammatory functions of human thrombomodulin in vivo.
Methods and Results—Knockin mice that express human thrombomodulin from the murine
thrombomodulin gene locus were generated. Compared with wild-type mice, human
thrombomodulin knockin mice exhibited decreased protein C activation in the aorta (P < 0.01) and
lung (P < 0.001). Activation of endogenous protein C following infusion of thrombin was
decreased by 90% in knockin mice compared with wild-type mice (P < 0.05). Carotid artery
thrombosis induced by photochemical injury occurred more rapidly in knockin mice (12 ± 3
minutes) than wild-type mice (31 ± 6 minutes; P < 0.05). No differences in serum cytokine levels
were detected between knockin and wild-type mice after injection of endotoxin. When crossed
with apolipoprotein E-deficient mice and fed a Western diet, knockin mice had a further decrease
in protein C activation but did not exhibit increased atherosclerosis.
Conclusion—Expression of human thrombomodulin in place of murine thrombomodulin
produces viable mice with a prothrombotic phenotype but unaltered responses to systemic
inflammatory or atherogenic stimuli. This “humanized” animal model will be useful for
investigating the function of human thrombomodulin under pathophysiological conditions in vivo.
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Thrombomodulin is an endothelial cell-surface thrombin receptor that modulates hemostasis
and inflammation.1–3 When bound to thrombomodulin, thrombin efficiently catalyzes
production of activated protein C (APC), a clinically important endogenous anticoagulant.
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APC downregulates coagulation by proteolytically inactivating factors Va and VIIIa. In
addition to its anticoagulant effects, APC inhibits endothelial inflammatory and cell death
pathways4 through a mechanism that involves protease activated receptor-1 and the
endothelial protein C receptor (EPCR).5–7 Thrombomodulin also modulates inflammation
independently of APC, possibly by activating anti-inflammatory pathways through its N-
terminal lectin domain,8–10 negatively regulating complement,11 or by facilitating the
activation of thrombin activatable fibrinolysis inhibitor, a procarboxypeptidase that may
modulate both fibrinolysis and complement-mediated inflammation.2
Several murine models of altered thrombomodulin gene structure have been developed.
Homozygous deletion of the murine thrombomodulin gene results in intrauterine lethality
before E10.5.12 The mechanism of embryonic death of thrombomodulin null embryos is
related to thrombin-induced growth arrest of trophoblast cells.13 Embryonic development is
not impaired in mice expressing thrombomodulin mutants with deletions of the C-terminal
cytoplasmic or N-terminal lectin domains.8, 14 Embryonic development also occurs
normally in mice with a thrombomodulin mutation (TMΔPro) that markedly reduces protein
C activation and predisposes mice to thrombosis during hypoxia.15 This observation
suggests that low levels of APC are sufficient for normal embryogenesis and placental
development.
Because of interspecies differences in thrombomodulin structure and function, current
murine models provide only limited insights into the pathophysiological role of human
thrombomodulin in vivo. We therefore sought to develop knockin mice that express human
thrombomodulin in the absence of murine thrombomodulin and to determine if such mice
can be used to investigate the function of human thrombomodulin under pathophysiological
conditions in vivo. Our results indicate that mice expressing human thrombomodulin from
the murine thrombomodulin gene locus are partially protected from embryonic lethality and
have normal post-natal development and survival. Compared with wild-type mice, human
thrombomodulin knockin mice have a prothrombotic phenotype characterized by decreased
protein C activation and enhanced susceptibility to experimental thrombosis but they do not
exhibit impaired systemic anti-inflammatory responses or enhanced susceptibility to
atherosclerosis. These findings reveal differential species-specific effects of murine and
human thrombomodulin in regulating thrombosis vs. inflammation, and demonstrate that the
human thrombomodulin knockin mouse is an instructive model for investigating the
pathophysiological role of human thrombomodulin in vivo.
METHODS
Generation of human thrombomodulin knockin mice
Two separate lines of human thrombomodulin knockin mice, designated Hn and Hthm, were
generated by targeted replacement of the murine thrombomodulin (Thbd) gene with the
homologous gene segment containing the human thrombomodulin (THBD) coding sequence
(see Supplemental Methods and Supplemental Figure I for details). Animal protocols were
approved by the University of North Carolina or University of Iowa Animal Care and Use
Committees.
Generation of Apoe−/− Hthm/Hthm mice
Apolipoprotein E (Apoe) null mice16 on the C57BL/6 background were obtained from The
Jackson Laboratory (Bar Harbor, ME) and crossbred with Hthm/+ mice for two generations
to generate littermate Apoe−/− mice that were either Hthm/Hthm or +/+ at the
thrombomodulin locus. Starting at three weeks of age, the mice were fed either a control diet
(LM485, Harlan Teklad, Madison, WI) or high fat “Western” diet (TD003159, Harlan
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Teklad) containing 20.3% fat. Experimental procedures were performed on male mice at 24
weeks of age. Blood from anesthetized mice was collected by cardiac puncture into EDTA
(final concentration 5 mmol/L) and plasma cholesterol was measured using the Infinity
Cholesterol Reagent kit (Thermo Electron Corporation; Louisville, CO).
Morphometric analysis of atherosclerotic lesions
Morphometric analyses of aortic sinus atherosclerotic lesion area was performed as
described previously.17 Briefly, hearts embedded in paraffin were sectioned at 8 μm serial
intervals through the entire aortic sinus. The sections were stained with the Verhoeff - van
Gieson method. Cross-sectional lesion area was calculated using the mean value of 5
sections, each 80 μm apart, beginning at the aortic valve leaflets and spanning 320 μm.
Measurement of thrombomodulin mRNA by quantitative PCR
Total RNA was isolated from lung, heart, or kidney of male mice using Trizol reagent. RNA
was treated with DNase I to remove contaminating genomic DNA, and then reverse
transcribed using Taqman reverse transcriptase reagents and random hexamer primers. Real-
time PCR was performed using a 7700HT sequence detection system (Applied Biosystems)
as described previously.18 Primers and probes were designed using Primer Express software
(Applied Biosystems) to be specific for either murine thbd (forward,
ATTTCCATTGCCAGCCTGTC; reverse, TGTACTCCAGCTCTGCACGA) or human
THBD (forward, ATCTCCATCGCGAGCCTGTG; reverse,
TGTACTCCATCTTGGCCCTG). A common probe (Fam-
CGCCCTGCTTCTTGCGCAGGT-Tamra) was used for both murine and human products.
Total amounts of thrombomodulin transcripts in Hthm/Hthm and +/+ mice were determined
using a probe/primer set that detects regions common to the mouse and human transcripts
(forward, GACAGCCCAGTTTCTTCCAA; reverse, TCTGGGATCTCCGCTGTATT;
probe, Fam-CCACCTCCGCCCAGTTGTCCAG-Tamra). Data were analyzed using the
comparative threshold cycle (ΔΔCT) method,19 with β-actin as the comparator, using
Sequence Detection software version 1.6.3 (Applied Biosystems).
Immunohistochemistry
Sections of formalin-fixed, paraffin-embedded lung or tail from adult mice were
deparaffinized, and endogenous peroxidase activity quenched with hydrogen peroxide.
Sections were blocked with Power Block (Biogenex, San Ramon, CA) and stained with a
1:50 dilution of mouse monoclonal anti-human thrombomodulin antibody
(DakoCytomation, Carpenteria, CA) in PBS. LSAB II linker-horseradish peroxidase
(DakoCytomation) was applied, and staining was visualized with diaminobenzidine
(DakoCytomation). Sections were counterstained with Harris hematoxylin without acid.
Thrombomodulin antigen
Lung lysates were prepared by homogenization in 0.02 M Tris-HCl, 0.1 M NaCl, 2% Triton
X-100 (pH 8.0) as described.20 Human thrombomodulin antigen was measured by ELISA
(Asserachrom Thrombomodulin, Diagnostica Stago, Franconville, France). To measure
mouse thrombomodulin antigen, immunoassay plates (Nunc-Immuno plate, PolySorp
surface, flat bottom, Nalge Nunc International, Rochester, NY) were coated overnight at 4°C
with 1 μg per well of polyclonal goat anti-mouse thrombomodulin (R&D Systems, Inc.,
Minneapolis, MN) in 20 mM carbonate (pH 9.2), 0.02% sodium azide. After washing 3
times, wells were blocked with 1% bovine serum albumin (Research Products International
Corp, Prospect, IL) in 50 mM Tris-HCl (pH 7.4), 150 mM NaCl. Lung lysate samples (40
μg protein per well) or recombinant mouse thrombomodulin (R&D Systems, Inc.) standard
samples were added and incubated for one hour at room temperature followed by washing.
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Monoclonal rat anti-mouse thrombomodulin (0.2 μg/well, R&D Systems, Inc.) was added
and incubated for one hour at room temperature. After 3 additional washes, anti-rat IgG-
alkaline phosphatase conjugate antibody (0.064 μg/well, Sigma-Aldrich, St. Louis, MO) was
added and incubated for one hour at room temperature. After 3 additional washes, para-
nitrophenol phosphate substrate (Sigma-Aldrich) was added and color development was
monitored at 405 nm in a 96-well plate reader (Spectra Max 190, Molecular Devices,
Woburn, MA). The standard curve was linear over a range of 0.1 to 2.0 nmol/L recombinant
mouse thrombomodulin. No cross-reactivity with recombinant human thrombomodulin was
detected at concentrations up to 4 nmol/L. The total protein concentration of lung lysates
was measured using a modified Bradford assay (Bio-Rad Laboratories, Richmond, CA).
Protein C activation
Activation of exogenous protein C by thrombin was measured in freshly isolated rings of
proximal aorta (1.0 mm in length), or in lung lysates, using a two-stage assay described
previously.20, 21 Activation assays were performed using either 2.6 nM human thrombin and
150 nM human protein C20 or 2.6 nM murine thrombin (Haematologic Technologies, Essex
Junction, VT) and 150 nM murine protein C.22 Reference curves were generated using
rabbit lung thrombomodulin (American Diagnostica, Stamford, CT). One unit of activity
was defined as the amount of APC generated in the presence of 1.0 nmol/L rabbit
thrombomodulin.
Activation of endogenous protein C was measured in response to infusion of human
thrombin in adult mice. Mice anesthetized with sodium pentobarbital (70–90 mg/kg) were
secured in a supine position under a dissecting microscope and ventilated mechanically with
room air and supplemental oxygen as described previously.21, 23 A heating pad was used to
maintain body temperature at 36–37°C. Human thrombin (Haematologic Technologies) (40
units/kg) or saline was rapidly infused into the right cardiac ventricle in a total volume of
100 μl. After 10 minutes, blood was collected by cardiac puncture into a 1/10th volume of
0.1 M sodium citrate containing 0.5 M benzamidine. The concentration of murine APC in
citrate/benzamidine-treated plasma was measured as described previously24 and reported as
percent of APC in a pool of normal mouse plasma. For experiments performed with Apoe−/
− Hthm/Hthm mice, murine APC was measured using an enzyme capture assay. Citrate-
anticoagulated plasma samples containing 30 mM benzamidine were added to Nunc
MaxiSorp plates (Fisher Scientific; Pittsburg PA) coated with 5 μg/ml anti-mouse APC
(AMGDPC 1587), a generous gift from Charles Esmon (Oklahoma Medical Research
Foundation, Oklahoma City, OK). The activity of bound APC was determined by incubation
for 24 hours at 37°C with Spectrozyme PCa (American Diagnostica, Inc., Stamford, CT),
followed by acid quenching and determination of absorbance using a microplate reader
(Spectra Max 190; Molecular Devices; Sunnyvale, CA). Mouse APC (Haematological
Technologies Inc., Essex Junction, VT) was used to standardize the assay.
Direct anticoagulant activity
To measure the direct anticoagulant activity of thrombomodulin, lung lysates were
incubated with 1 nM human α-thrombin (HT3054, Enzyme Research, South Bend, IL) and
bovine fibrinogen (1 mg/ml, Sigma, St. Louis, MO) and the time to clot formation was
measured using a fibrometer (BBL FibroSystem, Becton Dickinson, Franklin Lakes, NJ).
Glycosaminoglycan hydrolysis
To determine the effect of glycosaminoglycan (GAG) on thrombomodulin activity, lung
lysates were incubated for 16 hours at 37°C with or without chondroitin sulfate ABC lyase
(Seikagaku America, Falmouth, MA) at 0.2 units/mg protein final concentration in 50 mM
Tris-HCl containing 100 mM NaCl, 0.5 mM sodium acetate, leupeptin (20 μg/ml), pepstatin
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(10 μg/ml), and 2.5 mM o-phenanthroline, pH 8.0. The reaction was stopped by incubating
the solution at 90°C for 1 minute. To control for the efficiency of chondroitin sulfate lyase
activity, a chondroitin sulfate-containing proteoglycan (aggrecan) from rat
chondrosarcoma25 was added to the chondroitin sulfate lyase-lung lysate mixtures. The
mixtures were electrophoresed using 7.5% SDS-PAGE and stained with Coomassie blue to
detect a characteristic 94 kDa aggrecan peptide devoid of GAG.25 Protein C activation and
direct anticoagulant activity assays were then performed using chondroitin sulfate lyase-
treated or control lung lysates.
Carotid artery thrombosis
Carotid artery thrombosis was induced by photochemical injury as described.21, 23 Mice
anesthetized with sodium pentobarbital (70–90 mg/kg) were ventilated mechanically with
room air and supplemental oxygen. Blood flow in the right carotid artery was measured with
a 0.5 PSB Doppler flow probe (Transonic Systems, Ithaca, NY). To induce endothelial
injury, the right common carotid artery was transilluminated continuously with a 1.5-mV,
540 nm green laser (Melles Griot, Carlsbad, CA) from a distance of 6 cm, and rose bengal
(25 to 50 mg/kg) was injected via a femoral vein catheter. Blood flow was monitored
continuously for 90 minutes or until stable occlusion occurred. Stable occlusion was defined
as the time at which blood flow remained absent for ≥ 10 minutes.
Response to endotoxin
Endotoxin (E. coli bacterial LPS serotype 055:B5) was purchased from Sigma-Aldrich, St.
Louis, MO. Mice were injected intraperitoneally with 8 mg/kg LPS or saline in a volume of
100 μL. After 4 hours, serum was isolated for measurement of interleukin 6, interleukin 1β,
and tumor necrosis factor-α by Quantikine immunoassay kits (R&D Systems, Inc.
Minneapolis, MN). Plasma and serum were frozen at −80°C until assayed.
Statistical analyses
Comparisons between mouse genotypes were performed using the unpaired 2-tailed,
Student’s t-test or one-way ANOVA. Occlusion times were compared with the Mann-
Whitney rank sum test. Viability data were analyzed using the chi-square test. Statistical
significance was defined as a P value less than 0.05. Values are reported as mean ± SE.
Except where indicated, all statistical comparisons were performed between littermates and
all experimental groups included both female and male mice.
RESULTS
Generation and viability of human thrombomodulin knockin mice
Two separate lines of human thrombomodulin knockin mice, designated Hn and Hthm, were
generated by targeted replacement of the murine Thbd gene with the homologous gene
segment containing the human THBD coding sequence (Supplemental Figure I). The Hn line
contained a loxP-flanked (floxed) neomycin resistance gene within the thrombomodulin 3′
UTR. The Hthm line was generated by crossbreeding Hn/+ mice with transgenic mice
expressing Cre recombinase26 to excise the neomycin resistance gene.
In both the Hn and Hthm lines, the gross appearance of weaned heterozygous and
homozygous human thrombomodulin knockin mice was normal, and no abnormalities in
organ morphology or histology were observed. However, the number of viable homozygous
Hn/Hn or Hthm/Hthm mice produced from heterozygous matings was decreased from
expected Mendelian frequencies (Supplemental Tables I and II). Homozygous Hn/Hn mice
represented only 5% of weaned offspring (P < 0.05 vs. the expected Mendelian frequency of
25%). The frequency of homozygous Hthm/Hthm offspring at weaning (14%) was greater
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than for Hn/Hn homozygotes (P < 0.001), but was still less than the expected Mendelian
frequency (P < 0.05). There were no significant differences in the frequencies of
homozygous Hthm/Hthm or Hn/Hn offspring at weaning between mice on a 129/SvEv
inbred background vs. mice on a mixed background of 129/SvEv and C57BL/6. Hn/Hn and
Hthm/Hthm mice that survived weaning exhibited normal growth and survival. The mean
weights of Hn/Hn and Hthm/Hthm mice between 12 and 18 months of age did not differ
from +/+ mice (data not shown).
Because mice with complete deficiency of thrombomodulin uniformly die before day 10 of
embryogenesis,12 we sought to determine if the decreased viability of human
thrombomodulin knockin mice also was due to early embryonic lethality. The frequencies of
Hn/Hn and Hthm/Hthm fetuses isolated from heterozygous matings on E10.5 were 16% and
23%, respectively (Supplemental Tables I and II), which suggests that early embryonic
viability is relatively normal in human thrombomodulin knockin mice. On E17.5, the
frequencies of Hn/Hn and Hthm/Hthm fetuses had decreased to 6% and 13%, respectively,
quite similar to those observed at weaning. These findings suggest that homozygous
replacement of the murine thrombomodulin allele with the Hn or Hthm alleles resulted in the
partial loss of viability between E10.5 and E17.5. This effect on viability was more severe
for Hn/Hn mice than for Hthm/Hthm mice.
Expression of thrombomodulin mRNA
Levels of total (murine plus human) thrombomodulin mRNA were measured in lung and
heart isolated from adult +/+, Hthm/Hthm, and Hn/Hn mice using real-time PCR primers
that detect both murine and human transcripts (Table 1). The levels of total thrombomodulin
mRNA in the lung of Hthm/Hthm and Hn/Hn mice were not significantly different from
those in +/+ mice. In the heart, the levels of total thrombomodulin mRNA were similar in +/
+ and Hthm/Hthm mice, but were 50% lower in Hn/Hn mice than in +/+ mice (P < 0.05).
Levels of individual murine thrombomodulin and human thrombomodulin transcripts were
measured in +/+, Hthm/+, and Hn/+ mice using species-specific real-time PCR primers
(Table 2). Levels of murine thrombomodulin mRNA in the lung, heart, and kidney of Hthm/
+ mice were 50–60% lower than levels measured in +/+ mice (P < 0.05). Levels of murine
thrombomodulin mRNA in the lung, heart, and kidney of Hn/+ mice were 40–65% lower
than those in +/+ mice (P < 0.05). These findings indicate that the presence of the targeted
allele in heterozygous Hthm/+ or Hn/+ mice does not have a major influence on
thrombomodulin expression from the wild-type allele. As expected, human thrombomodulin
mRNA was not detected in +/+ mice. The relative expression of human thrombomodulin
mRNA in the lung and kidney was similar in Hthm/+ and Hn/+ mice. In the heart, there was
a trend toward lower levels of human thrombomodulin mRNA in Hn/+ mice compared with
Hthm/+ mice (8 ± 2 vs. 15 ± 4%; P = 0.24), a finding that is consistent with the lower level
of total thrombomodulin mRNA in the heart of Hn/Hn mice (Table 1).
Expression of human thrombomodulin protein
Expression of human thrombomodulin protein in Hthm/+ and Hthm/Hthm mice was
demonstrated by immunohistochemistry and ELISA (Figure 1). Immunohistochemical
staining of tail cross-sections using a monoclonal anti-human thrombomodulin antibody was
strongly positive in endothelium and keratinocytes in Hthm/Hthm mice, moderately positive
in Hthm/+ mice, and negative in +/+ mice (Figure 1, A–C). This expression pattern is
consistent with that observed previously for thrombomodulin in mice and humans.27, 28
Immunofluorescence staining of lung sections also revealed endothelium-specific staining
for human thrombomodulin in Hthm/+ and Hthm/Hthm mice, whereas staining for murine
thrombomodulin was detected in +/+ and Hthm/+ mice (Supplemental Figure III). Co-
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localization of murine and human thrombomodulin was observed in lung endothelium
(Supplemental Figure IV).
Human thrombomodulin antigen levels measured by ELISA in lung lysates were concordant
with immunohistochemical observations (Figure 1D). Human thrombomodulin antigen was
approximately twice as high in Hthm/Hthm mice compared with Hthm/+ mice (P = 0.01).
Murine thrombomodulin antigen levels measured by ELISA in lung lysates were decreased
by approximately 70% in Hthm/+ mice compared with +/+ mice (P < 0.01) (Figure 1E).
Protein C activation
Activation of protein C in aortic rings and lung lysates was measured in vitro using human
protein C and human thrombin. Generation of APC was similar in aortic rings from +/+ and
Hthm/+ mice (Figure 2A). APC generation was decreased by 28% in aortic rings from Hn/+
mice (P < 0.05 vs. +/+ mice), and by approximately 60% in aortic rings from both Hthm/
Hthm and Hn/Hn mice (P < 0.01 vs. +/+ mice). With lung lysates (Figure 2B), generation of
APC was decreased by approximately 50% for Hthm/+ and Hn/+ mice (P < 0.05 vs. +/+
mice), 75% for Hthm/Hthm mice (P < 0.001 vs. +/+ mice), and 90% for Hn/Hn mice (P <
0.05 vs. +/+ mice). To determine if differences in protein C activation also occurred with
murine reagents, activation of murine protein C was measured with lung lysates from +/+,
Hthm/+, and Hthm/Hthm mice using murine thrombin. Compared with lysates from +/+
mice, lysates from Hthm/+ mice generated 52% less APC (P < 0.05) and lysates from Hthm/
Hthm mice generated 86% less APC (P < 0.001) (Figure 2C).
Activation of endogenous murine protein C in vivo was assessed by measuring plasma levels
of APC in +/+, Hthm/+, and Hthm/Hthm mice following infusion of saline vehicle or 40 U/
kg human thrombin (Figure 2D). Compared with infusion of saline, infusion of thrombin
produced a 2.7-fold increase in plasma APC concentration in +/+ mice (P < 0.05) but no
significant increase in Hthm/+ or Hthm/Hthm mice.
Effect of glycosaminoglycan hydrolysis on thrombomodulin activity
To determine if the decreased thrombomodulin activity of human thrombomodulin knockin
mice was caused by differential effects of GAG attachment to thrombomodulin, lung lysates
from +/+ or Hthm/Hthm mice were incubated with chondroitin sulfate ABC lyase prior to
performing protein C activation or direct anticoagulant activity assays. The protein C
activation activity of thrombomodulin in lung lysates from +/+ or Hthm/Hthm mice was not
significantly affected by treatment with chondroitin sulfate lyase (Supplemental Figure VA).
In contrast, the direct anticoagulant activity of thrombomodulin (i.e. the ability of
thrombomodulin to directly inhibit the fibrinogen cleaving activity of thrombin), which is
highly sensitive to its GAG content,29 was decreased by approximately 40% after GAG
hydrolysis in both the +/+ and Hthm/Hthm samples (Supplemental Figure VB). These results
suggested that GAG attachment contributes equivalently to the direct anticoagulant activity
of murine and human thrombomodulin expressed in mouse lung.
Carotid artery thrombosis
The time to thrombotic occlusion of the carotid artery after photochemical injury was
measured in +/+, Hthm/+, and Hthm/Hthm mice (Figure 3). Occlusion times did not differ
between +/+ and Hthm/+ mice, but the mean time to stable occlusion was decreased by more
than 60% in Hthm/Hthm mice (12 ± 3 minutes) compared with +/+ mice (31 ± 6 minutes) (P
< 0.05).
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The inflammatory response to intraperitoneal injection of a sublethal dose of 8 mg/kg E. coli
LPS was determined by measurement of serum cytokine levels in +/+ and Hthm/Hthm mice
4 hours after LPS administration. Serum levels of IL-6 (Figure 4A), IL-1β (Figure 4B), and
TNFα (Figure 4C) all increased significantly and equivalently after LPS administration in +/
+ and Hthm/Hthm mice (P < 0.05 vs. saline).
Phenotype of Apoe−/− Hthm/Hthm mice
To determine the effects of hypercholesterolemia in human thrombomodulin knockin mice,
Apoe−/− mice were crossbred with Hthm/+ mice for two generations to generate littermate
Apoe−/−mice that were either Hthm/Hthm or +/+ at the thrombomodulin locus. Starting at
three weeks of age, male mice were fed either a control diet or high fat “Western” diet until
they were studied at 24 weeks of age. Compared with the control diet, the high fat diet
produced a similar 2-fold increase in plasma total cholesterol levels in Apoe−/− and Apoe−/
− Hthm/Hthm mice (P < 0.01) (Figure 5A). The high fat diet also produced similar increases
in cross-sectional atherosclerotic lesion area, measured in the aortic sinus, compared with
the control diet in Apoe−/− and Apoe−/− Hthm/Hthm mice (P < 0.01) (Figure 5B).
Following infusion of thrombin, circulating plasma levels of APC were significantly lower
in Apoe−/− Hthm/Hthm mice compared with littermate Apoe−/− mice fed either the control
or high fat diets (P < 0.01) (Figure 5C). Notably, the amount of circulating APC generated in
Apoe−/− Hthm/Hthm mice was significantly lower with the high fat diet than the control
diet (P < 0.05). Finally, the time to stable thrombotic occlusion of the carotid artery after
photochemical injury was decreased markedly in Apoe−/− or Apoe−/− Hthm/Hthm mice fed
the high fat diet (P < 0.05) (Figure 5D), confirming that hypercholesterolemia induces a
prothrombotic phenotype in mice expressing either murine or human thrombomodulin.
DISCUSSION
We generated knockin mice that express human thrombomodulin in the absence of murine
thrombomodulin. Human thrombomodulin knockin mice exhibited a prothrombotic
phenotype, with decreased activation of protein C in vivo following thrombin infusion and
an accelerated thrombotic response to carotid artery injury. Interestingly, exposure to
endotoxin produced identical systemic cytokine responses in wild-type and human
thrombomodulin knockin mice, which suggests that despite their markedly different
anticoagulant profiles, mice expressing murine and human thrombomodulin have similar
inflammatory responses in vivo. Mice expressing human or murine thrombomodulin also
had similar susceptibilities to atherosclerosis when crossed to an apolipoprotein E-deficient
background. Interestingly, hypercholesterolemia produced a significant impairment of
protein C activation in mice expressing human thrombomodulin, which demonstrates the
potential utility of the human thrombomodulin knockin mouse as a pathophysiological
model for the study of human thrombomodulin function in conditions such as
atherosclerosis.
Expression of human thrombomodulin in place of murine thrombomodulin partially
bypassed the uniform embryonic lethality that occurs with complete deficiency of murine
thrombomodulin.12 Approximately 50% of mice homozygous for the Hthm allele and 80%
of mice homozygous for the Hn allele died between E10.5 and E17.5 (Supplemental Table
I). Thrombomodulin is expressed in both trophoblasts and developing endothelium early in
embryogenesis.1 The mechanism of early embryonic death of thrombomodulin null embryos
appears to be caused by growth arrest of trophoblast cells.13 Reconstitution of murine
thrombomodulin expression in placental tissue rescues thrombomodulin null embryos from
early embryonic lethality, and reveals a secondary developmental block between days 12.5
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and 16.5 that is caused by lack of thrombomodulin expression in endothelium.13, 30 Our
findings suggest that human thrombomodulin can functionally substitute for murine
thrombomodulin to bypass the early trophoblast-dependent developmental block, but only
partially bypass the later, endothelium-dependent developmental block. The more severe
embryonic loss in Hn/Hn mice compared with Hthm/Hthm mice may be due to slightly
lower expression of human thrombomodulin in some tissues (Table 1), likely caused by the
presence of the neomycin resistance gene within the 3′UTR of the Hn allele.
Compared with wild-type mice, human thrombomodulin knockin mice were hypomorphic
for thrombomodulin activity and exhibited a prothrombotic phenotype, with a 50%
shortening in the time to carotid artery occlusion following photochemical injury. The
prothrombotic phenotype of human thrombomodulin knockin mice contrasts with the
antithrombotic phenotype of human thrombomodulin transgenic mice reported recently by
Crikis et al.31 An important distinction between these models is that the transgenic mouse
model described by Crikis et al. is a thrombomodulin overexpression model in which the
human thrombomodulin transgene is expressed in addition to endogenous murine
thrombomodulin. Overexpression of (human + murine) thrombomodulin in these mice
results in increased APC generation and protection from thrombosis.31 In contrast, the
human thrombomodulin knockin mouse model reported here is a hypomorphic model in
which human thrombomodulin is expressed instead of murine thrombomodulin. Compared
with +/+ mice, Hthm/Hthm mice had similar levels of thrombomodulin mRNA expression
(Table 1) and higher levels of thrombomodulin antigen in the lung (Figure 1). These
findings suggest that the prothrombotic phenotype (decreased protein C activation and
enhanced susceptibility to arterial thrombosis) in Hthm/Hthm mice is unlikely to be caused
by an alteration in thrombomodulin expression. Instead, the findings suggest that human
thrombomodulin may be a less active anticoagulant than murine thrombomodulin in vivo.
We explored the possibility that differences in protein C activation between wild-type and
human thrombomodulin knockin mice may be related to differences in modification by O-
linked chondroitin sulfate GAG chains. Thrombomodulin’s GAG chains provide secondary
thrombin binding sites and enhance its anticoagulant function.32, 33 Both murine and human
thrombomodulin contain GAG attachment consensus sequences within their serine/threonine
rich domains.34 In human thrombomodulin, the primary GAG attachment site is serine
474.35 Mouse thrombomodulin has a homologous serine attachment site, but the flanking
sequence contains a series of three acidic residues that may enhance the efficiency of GAG
attachment.36 Despite these sequence differences, when human and murine thrombomodulin
were treated with chondroitin sulfate ABC lyase to remove GAG, no significant effects on
protein C activation were observed (Supplemental Figure V). The direct anticoagulant
function of both murine and human thrombomodulin was decreased by GAG removal, but
the effects were similar for +/+ and Hthm/Hthm mice. These results indicate that GAG
attachment plays an equivalent role in the anticoagulant activity of murine and human
thrombomodulin and suggest that the prothrombotic phenotype of human thrombomodulin
knockin mice is not due to differential effects of GAG. It is more likely, therefore, that
structural changes due to amino acid differences are responsible for the more potent
antithrombotic activity of murine compared with human thrombomodulin.
It is possible but unlikely that the decreased protein C activation in human thrombomodulin
knockin mice is related to the presence of the A455V polymorphism within the 6th EGF
domain. This common human thrombomodulin polymorphism has been found to be
associated with arterial thrombosis in some studies, but several large population studies have
failed to confirm this association.37, 38 Several other candidate prothrombotic
thrombomodulin mutations have been identified in human subjects with venous or arterial
thrombosis, but the clinical significance of these gene variants remains uncertain.37–39
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Mutations that impair the function of thrombomodulin were recently described in some
patients with atypical hemolytic uremic syndrome.40 The thrombomodulin knockin
approach described in this study could potentially be utilized to directly examine the
pathophysiological consequences of these and other human thrombomodulin gene variants.
Despite considerable progress in defining the role of thrombomodulin and the protein C
activation pathway in susceptibility to thrombosis and modulation of inflammatory
responses, the impact of this anticoagulant pathway on atherosclerosis is less well
understood.41 Eitzman et al. observed accelerated atherogenesis in Apoe−/− mice expressing
the murine equivalent of the human factor V Leiden mutation, which confers resistance to
APC.42 Seehaus et al. found that expression of a hypomorphic murine thrombomodulin
mutation (TMΔPro) in Apoe−/− mice had paradoxical effects on atherosclerosis; the
atherosclerotic lesions were larger but also had histological features suggestive of enhanced
plaque stability.43 These observations raise the question of whether human thrombomodulin
confers protection or susceptibility to atherosclerosis. Our findings indicate that mice
expressing human or murine thrombomodulin have similar susceptibilities to atherosclerosis
when crossed to the Apoe−/− background despite their differing anticoagulant activities.
The contrasting effects on atherosclerosis of the murine TMΔPro mutant studied by Seehaus
et al. and human thrombomodulin in our study could be due to a relatively lower
anticoagulant activity of the TMΔPro mutant.15 Alternatively, these findings might suggest
that human thrombomodulin has protective effects on atherosclerosis that are independent of
its anticoagulant activity. In either case, our results suggest that the human thrombomodulin
knockin mouse may be an informative in vivo model for future studies investigating the role
of human thrombomodulin in atherosclerosis and other pathophysiological conditions.
A limitation of many mouse models is that there often are species-specific functional
differences between human and murine proteins that may alter responses to
pathophysiological conditions or pharmacological interventions. The generation of human
thrombomodulin knockin mice is a step toward humanizing the entire protein C system in
mice. Such humanization might facilitate the discovery of small molecules that modify the
human anticoagulant system and to study in in vivo consequences of such modifications.
The current model is limited because only the thrombomodulin gene locus was humanized
and it is not possible to directly compare the functional activities of human versus murine
thrombomodulin because of differences in their expression levels. Nevertheless, the
availability of this model, as well as other similar models such as the humanized tissue
factor mouse44 may enhance the clinical relevance of mouse models of human thrombotic
disease.
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Expression of human thrombomodulin protein by immunohistochemistry and ELISA.
Representative tail sections from +/+ (A), Hthm/+ (B), or Hthm/Hthm (C) mice were stained
with anti-human thrombomodulin antibody as described in Methods. Intense staining for
human thrombomodulin in endothelium and keratinocytes is demonstrated in Hthm/Hthm
mice, moderate staining in seen in Hthm/+ mice, and no specific staining is observed in +/+
mice. Lung lysates of +/+, Hthm/+, or Hthm/Hthm mice were analyzed for human (D) or
murine (E) thrombomodulin antigen by ELISA. Mice were studied at 3 months of age.
Values represent mean ± SE (n = 6 to 20 in each group). *P < 0.05 vs. +/+ mice.
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Protein C activation. Thrombomodulin-dependent activation of protein C was measured in
aortic rings (A) or lung lysates (B) of +/+, Hthm/+, Hthm/Hthm, Hn/+, or Hn/Hn mice using
2.6 nM human thrombin and 150 nM human protein C. Mice were studied at 3 months of
age. Values represent mean ± SE (n = 4 for Hn/Hn mice; N = 19 to 22 for all other groups).
*P < 0.05 vs. +/+ mice. (C) Thrombomodulin-dependent activation of protein C was
measured in lung lysates of +/+, Hthm/+, or Hthm/Hthm mice using 2.6 nM murine
thrombin and 150 nM murine protein C (n = 3 to 8 in each group). *P < 0.05 vs. +/+ mice.
(D) Plasma levels of murine APC were measured following infusion of either saline vehicle
or 40 U/kg of human thrombin. Results are reported as percent of APC in pooled normal
mouse plasma (n = 5 to 8 in each group). Mice were studied at 3 months of age. Values
represent mean ± SE. *P < 0.05 vs. saline.
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Carotid artery thrombosis following photochemical injury. Susceptibility to thrombosis in +/
+, Hthm/+, or Hthm/Hthm mice was assessed by measuring the time to stable occlusion after
photochemical injury of the carotid artery in anesthetized, ventilated mice. Mice were
studied at 6 months of age. Thrombosis was induced by injection of 35 to 50 mg/kg of rose
bengal. Values represent mean ± SE (n = 9 to 10 in each group). *P < 0.05 vs. +/+ mice.
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Response to intraperitoneal injection of endotoxin. Blood samples were obtained 4 hours
after intraperitoneal injection of 8 mg/kg LPS or saline vehicle in +/+ and Hthm/Hthm mice,
and were assayed for serum IL-6 (A), serum IL-1β (B), and serum TNFα (C). Mice were
studied at 12–18 months of age. Values represent mean ± SE (n = 5 to 13 in each group). #P
< 0.05 vs. saline.
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Phenotype of Apoe−/− Hthm/Hthm mice. Plasma total cholesterol levels (A), and aortic
sinus lesion area (B) in male Apoe−/− or Apoe−/− Hthm/Hthm mice fed either a control diet
or a high fat Western diet and studied at 24 weeks of age. (C) Plasma levels of murine APC
(reported as ng/mL) following infusion of 40 U/kg of human thrombin. (D) Time to stable
occlusion of the carotid artery thrombosis following photochemical injury. Thrombosis was
induced by injection of 25 mg/kg of rose bengal. Values represent mean ± SE (n = 6 to 13 in
each group). *P < 0.05 vs. control diet; #P < 0.05 vs. Apoe−/− mice.
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Table 1
Quantitative PCR analysis of total (murine + human) thrombomodulin mRNA†
+/+ Hthm/Hthm Hn/Hn
Lung 100±19 72±19 76±8
Heart 26±4 20±2 13±2*
†
The total amount of thrombomodulin mRNA was determined using a probe/primer set that detects regions common to the murine and human
transcripts. All mice were on an inbred 129/SvEv background, and were studied at 4–6 months of age. Data are reported as a percentage of the total
amount of thrombomodulin mRNA in the lung of +/+ mice. Values represent mean ± SE (n = 4 to 5 in each group).
*
P < 0.05 vs. +/+ mice.
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Table 2
Species-specific quantitative PCR analysis of thrombomodulin mRNA†
+/+ Hthm/+ Hn/+
Lung
 murine TM mRNA (%) 100±20 43±13* 35±11*
 human TM mRNA (%) 0±0 30±6* 26±9*
Heart
 murine TM mRNA (%) 14±2 6±1* 7±2*
 human TM mRNA (%) 0±0 15±4* 8±2*
Kidney
 murine TM mRNA (%) 8±1 4±1* 5±1
 human TM mRNA (%) 0±0 3±0.4* 4±2*
†
Levels of individual murine thrombomodulin and human thrombomodulin transcripts were measured using species-specific real-time PCR
primers. All mice were on an inbred 129/SvEv background, and were studied at 4–6 months of age. Data are reported as a percentage of murine
thrombomodulin mRNA in the lung of +/+ mice. Values are mean ± SE (n = 4 to 7 in each group).
*
P < 0.05 vs. +/+ mice.
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